Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates is a phase 2, interventional study registered as NCT07292298 by University of Colorado, Denver, with a registry enrolment figure of 44 participants, started 2026-11 and due to reach its primary completion in 2030-11. Interventions recorded: High Rare Dose Rectal Brachytherapy Boost. Conditions listed: Rectal Adenocarcinoma; Rectal Cancer. Primary outcome: Organ preservation (no surgical requirement) of the rectum associated with complete clinical response. Colorectal eligibility wording from the registry: "Patients with MMR-proficient low-mid rectal adenocarcinoma cT1-4 N0-2 M0 who underwent total neoadjuvant therapy who have not achieved complete response (i". Sites: United States. No results are recorded here; the registry entry is the source.